Neothetics to Provide a Business Update and Release Second Quarter 2016 Financial Results Thursday, August 11, 2016
August 04 2016 - 8:00AM
Neothetics, Inc. (NASDAQ:NEOT) today announced that it will provide
a business update and release its second quarter 2016 financial
results before the market opens on Thursday, August 11, 2016.
To receive Neothetics' press releases and other investor
information, please go to the Investor Relations page of the
company's website at investors.neothetics.com and register for
email alerts.
About Neothetics, Inc.
Neothetics is a clinical-stage specialty pharmaceutical company
focused on development and commercialization of therapeutics for
the aesthetic market. Our current focus is on localized fat
reduction and body contouring. Neothetics’ product candidate,
LIPO-202, is a potential injectable treatment for undesirable,
localized areas of fat that requires no pain management before or
after treatment and no downtime without damage to nearby tissues.
For more information on Neothetics, please visit
www.neothetics.com. Neothetics, LIPO-202, LIPO-102 and the
Neothetics logo are trademarks or registered trademarks of
Neothetics, Inc. Other names and brands may be claimed as the
property of others.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, statements regarding the
ability to develop a modified formulation of LIPO-202, timing of
conducting and obtaining results from Phase 2 trials and proof of
concept study with a modified formulation of LIPO-202, whether our
modified formulation of LIPO-202 is able to demonstrate positive
results, Neothetics’ plans to research, develop and
commercialize LIPO-202 and other product candidates, as well as
expected timing for reporting results from clinical trials. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. These forward-looking statements
are based upon Neothetics’ current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks and uncertainties associated
with clinical trials, such as the ability to timely initiate
clinical trials and enroll a sufficient number of patients on a
timely basis into clinical trials, the extent to which top-line
data is available and whether the clinical trials achieve positive
results, product development activities, obtaining regulatory
approval to commercialize LIPO-202 and other product candidates,
the company’s use of cash and the need to raise additional funding,
when needed, in order to conduct our clinical trials and other
business, the degree of market acceptance of LIPO-202 by
physicians, patients and others in the medical community, our
reliance on third parties, including third-party suppliers for
manufacturing and distribution of products, regulatory developments
in the United States and foreign countries, Neothetics’ ability to
obtain and maintain intellectual property protection for LIPO-202
and its product candidates, competition in the aesthetics industry
and other market conditions. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Neothetics undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
Investors should consult all of the information set forth herein
and should also refer to the risk factor disclosure set forth in
the reports and other documents the company files with
the SEC available at www.sec.gov, including without
limitation, Neothetics’ Form 10-K for the year ended December 31,
2015 and subsequent Quarterly Reports on Form 10-Q.
COMPANY CONTACTS:
Susan A. Knudson
Chief Financial Officer
858-500-7780
sknudson@neothetics.com
Fara Berkowitz, R.Ph, Pharm.D
Senior Director, Investor Relations and Corporate Development
646-494-1589
fberkowitz@neothetics.com
NEOTHETICS, INC. (NASDAQ:NEOT)
Historical Stock Chart
From Apr 2024 to May 2024
NEOTHETICS, INC. (NASDAQ:NEOT)
Historical Stock Chart
From May 2023 to May 2024